



DT07 Rec'd PCT/PTO 1 2 NOV 2004

1615  
PET

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 11-10-04

Signature:

Maura A. Gallagher  
(Maura A. Gallagher)

Docket No.: ASZD-P01-555  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Korsgren et al.

Application No.: 10/502069

Confirmation No.: 3992

Filed: July 21, 2004

Art Unit: 1615

For: THE USE OF MELAGARTRAN FOR THE  
MANUFACTURE OF A MEDICAMENT  
FOR THE TREATMENT OF TYPE 1  
DIABETES MELLITUS

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent,

publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. ASZD-P01-555. A duplicate copy of this paper is enclosed.

Dated: November 10, 2004

Respectfully submitted,

By 

David P. Halstead

Registration No.: 44,735

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/502069
				Filing Date	July 21, 2004
				First Named Inventor	Olle Korsgren
				Art Unit	1615
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	ASZD-P01-555

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	WO-00/45837	08-10-2000	Corline Systems AB		
	BB	WO-94/29336	12-22-1994	AstraAktiebolag		
	BC	WO-00/41716	07-20-2000	AstraZeneca AB		
	BD	WO-97/23499	07-03-1997	AstraAktiebolag		
	BE	WO-02/36157	05-10-2002	AstraZeneca AB		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Shapiro, A.M. James, et al., "Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen," The New England Journal of Medicine, 343(4):230-238 (2000)	
	CB	Ozmen, L., et al., "Inhibition of Thrombin Abrogates the Instant Blood-Mediated Inflammatory Reaction Triggered by Isolated Human Islets, Possible Application of the Thrombin Inhibitor Melagatran in Clinical Islet Transplantation," Diabetes, 51:1779-1784 (2002)	
	CC	Boker, A., et al., "Human Islet Transplantation: Update," World J. Surg., 25:481-486 (2001)	
	CD	Bennet, W., et al., "Incompatibility Between Human Blood and Isolated Islets of Langerhans, A Finding With Implications for Clinical Intraportal Islet Transplantation?" Diabetes, 48:1907-1914 (1999)	
	CE	Sefton, M.V., et al., "Making microencapsulation work: conformal coating, immobilization gels and in vivo performance," Journal of Controlled Release, 65:173-186 (2000)	
	CF	Hill, R.S., et al., "Immunoisolation of Adult Porcine Islets for the Treatment of Diabetes Mellitus, The Use of Photopolymerizable Polyethylene Glycol in the Conformal Coating of Mass-isolated Porcine Islets," Annals of the New York Academy of Sciences, 831:332-343	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--